UPDATES

Health notices · Tuesday 17 November

3 notices from the agencies today, in plain words, each with the original linked.

FDA approval of AMJEVITA (adalimumab-atto) injection

FDA · Approval

If you have moderately to severely active rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease, ulcerative colitis, or certain other inflammatory conditions, the FDA has approved AMJEVITA (adalimumab-atto) for treatment.

AMJEVITA is also approved for polyarticular juvenile idiopathic arthritis and non-infectious uveitis in eligible age groups, as well as chronic plaque psoriasis and hidradenitis suppurativa for certain patients.

This approval means AMJEVITA is now available as a tumor necrosis factor (TNF) blocker option to reduce signs and symptoms and, for some conditions, help inhibit structural damage and improve physical function.

Read the original notice

DELFLEX peritoneal dialysis solution recall for possible sterility issues

FDA · Recall

If you use peritoneal dialysis solution at home, this may affect you. The FDA notice describes complaints of potential leaks from small perforations in the print area on the primary bag in affected lots.

Because the product is meant to be sterile, leaks raise concerns about lack of assurance of sterility. The notice applies to DELFLEX Peritoneal Dialysis Solution with 4.25% dextrose, low magnesium/low calcium, with an attached Safe Stay Exchange Set.

The FDA says this recall is for affected lots distributed nationwide in the USA. The notice was published 2026-11-11.

The next steps are not listed in the notice excerpt provided. If you have this specific product, contact the clinic or pharmacy that supplies it to check whether your lot is affected.

Read the original notice

FDA approval of clindamycin hydrochloride capsules

FDA · Approval

If you need treatment for a serious infection caused by susceptible anaerobic bacteria, or certain streptococci, staphylococci, or pneumococci, clindamycin may be an option the FDA approved.

The label says use should be reserved for penicillin-allergic patients or when a clinician decides penicillin is inappropriate. It also notes a boxed warning about colitis, so clinicians should consider less toxic alternatives first.

If your clinician considers this medicine, they should base the choice on the infection type and available culture/susceptibility results when possible.

What to do

Read the original notice

- Discuss whether clindamycin is appropriate for you, considering penicillin alternatives and the risk of colitis as stated in the boxed warning.

Where this comes from

- FDA approval of AMJEVITA (adalimumab-atto) injection

  US Food and Drug Administration - Drugs@FDA · https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761024
- DELFLEX peritoneal dialysis solution recall for possible sterility issues

  US Food and Drug Administration - enforcement report · https://www.fda.gov/drugs/drug-safety-and-availability/drug-recalls
- FDA approval of clindamycin hydrochloride capsules

  US Food and Drug Administration - Drugs@FDA · https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=065442